ALX Oncology Holdings Inc. (ALXO)
Nasdaq · Healthcare · Biotechnology
$1.21−0.82%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $167M
- 52-week range
- $1.05 – $2.66
- 52-week change
- −33.33%
- EPS (trailing)
- −$1.13
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Net income
- −$102M
- Diluted EPS
- −$1.90
- Free cash flow
- −$84.3M
From the company’s annual report on SEC EDGAR.
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University.
Headquarters: South San Francisco, United States · 48 employees · alxoncology.com